Dorothy Dada, MD
Neurology · Santa Monica, CANPI 1528479383
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,306 of the $52,315 with a category attached, or 75.1%. AbbVie accounts for 82.4% of it on its own, with 35 other manufacturers making up the rest. Among neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 455 payments — averaging $114.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$43K
- Pfizer$4K
- Teva Pharmaceuticals USA, Inc.$605
- Lilly USA, LLC$601
- SK Life Science, Inc.$544
- Lundbeck LLC$449
- plus $3K from 30 others
What the payments were for
- Speaking & faculty fees$39,30675%
- Travel & lodging$2,4375%
- Food & beverage$10,44420%
- Education$1280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 212 | $43,088 |
| Pfizer | 46 | $4,024 |
| Teva Pharmaceuticals USA, Inc. | 25 | $605 |
| Lilly USA, LLC | 26 | $601 |
| SK Life Science, Inc. | 16 | $544 |
| Lundbeck LLC | 21 | $449 |
| Amgen | 11 | $390 |
| Upsher-smith Laboratories LLC | 16 | $295 |
| Biohaven Pharmaceuticals, Inc. | 11 | $274 |
| Regeneron Healthcare Solutions, Inc. | 7 | $215 |
| Axsome Therapeutics, Inc. | 8 | $194 |
| Merz North America, Inc. | 5 | $165 |
| Novartis | 2 | $149 |
| Sanofi | 4 | $144 |
| UCB, Inc. | 5 | $140 |
| Acadia Pharmaceuticals Inc | 1 | $113 |
| Currax Pharmaceuticals LLC | 6 | $109 |
| Gilead | 1 | $100 |
| Johnson & Johnson(2 entities) | 2 | $64 |
| Irhythm Technologies, Inc. | 2 | $63 |
| Scilex Pharmaceuticals Inc. | 3 | $62 |
| Amneal Pharmaceuticals LLC | 4 | $61 |
| Neurocrine Biosciences, Inc. | 2 | $56 |
| Cala Health, Inc. | 2 | $50 |
| Tonix Medicines, Inc. | 2 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $46 |
| Impel Pharmaceuticals Inc. | 2 | $45 |
| Arbor Pharmaceuticals, Inc. | 2 | $35 |
| EMD Serono, Inc. | 1 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Collegium Pharmaceutical, Inc. | 2 | $27 |
| AstraZeneca | 1 | $25 |
| Metuchen Pharmaceuticals | 1 | $21 |
| Assertio Therapeutics, Inc. | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Misonix Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,315 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 57 | $45,469 |
| Nurtec OdtRimegepant Sulfate | 35 | $42,827 |
| QuliptaAtogepant | 19 | $29,707 |
| Aimovig AutoinjectorErenumab-Aooe | 25 | $18,025 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 12 | $8,851 |
| Gabapentin | 199 | $4,057 |
| Levetiracetam | 60 | $2,620 |
| Propranolol Hcl ErPropranolol Hcl | 12 | $2,326 |
| Lacosamide | 18 | $2,082 |
| Memantine Hcl | 81 | $1,887 |
| Carbamazepine ErCarbamazepine | 14 | $1,318 |
| Lamotrigine | 66 | $1,305 |
| Pregabalin | 35 | $1,228 |
| Sumatriptan Succinate | 46 | $1,065 |
| Duloxetine Hcl | 32 | $590 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $4,024 | $42,82735 claims |
| AbbVieQulipta | $43,088 | $29,70719 claims |
| Upsher-smith Laboratories LLCTopiramate | $295 | $12311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.
Other neurology in Santa Monica
- David KudrowSanta Monica$532K
- Santosh KesariSanta Monica$397K
- Andrew WooSanta Monica$273K
- Danny BenmosheSanta Monica$268K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.